Genes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by ...

Radnet Inc. expanded its commitment to the use of AI in improving diagnosis of breast cancer with an all-stock purchase of Icad Inc. for approximately $103 million. The transaction is expected to ...

In a blast from the past, U.S. President Donald Trump signed an executive order April 15 to deliver on his 2016 campaign promises and strengthen or reinstate efforts of his first administration to ...

Oral peptide delivery specialist Cyprumed GmbH is about to find out if the high bioavailability of its tablet formulations seen in animal models will translate across to humans, after signing a $493 ...

Johnson & Johnson’s Medtech division reported the completion of the first cases in the clinical trial for the Ottava robotic ...

Biopharma dealmaking surged in the first quarter of 2025, totaling $66.86 billion, well ahead of the $44.16 billion recorded ...

The Trump administration sent several signals about the imposition of tariffs on semiconductors – a vital component for many devices. While imaging systems sell infrequently and may not suffer from a ...

Cutaneous melanoma nearly always arises on parts of the body that receive abundant sun but, rarely, it can arise on parts that do not, such as the palms of the hands or soles of the feet. These rare ...

The Center for Medicare and Medicaid Innovation was founded with the objective of reducing Medicare spending, but many of the associated programs will be stood down by the end of this year thanks in ...

Huons Global Co. Ltd. has described reversible H+/K+ ATPase inhibitors, particularly acid pump antagonists (APA), reported to be useful for the treatment of gastric and duodenal ulcers, gastritis, ...

Praetego Inc. and University of California San Diego scientists reported preclinical results for the new small-molecule amadorin PTG-630, a brain-penetrant drug candidate that inhibits the formation ...

After dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the rare genetic neurodegenerative ...